Respiratory Syncytial Virus Infections Clinical Trial
— TreatRSV1Official title:
A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients
Verified date | June 2019 |
Source | Pulmocide Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study tests the effects of an experimental drug PC786 in people infected with Respiratory Syncytial Virus (RSV). PC786 may be useful in treating patients infected with RSV as it works by interfering with the way the virus multiplies. PC786 is an inhaled medicine. Participants will be treated with SoC treatment (e.g. oral ribavirin and/or IV immunoglobulin), half of the participants will receive PC786 in addition and half will receive a placebo treatment. The study will take place at multiple sites in UK and will include approximately 30 participants. The maximum study duration will be about 4 weeks.
Status | Terminated |
Enrollment | 5 |
Est. completion date | May 1, 2019 |
Est. primary completion date | February 19, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Received an allogeneic or autologous hematopoietic stem cell transplant (HSCT) using any conditioning regimen - Experienced new onset of at least one of the following respiratory symptoms =5 days before study Day 1: Nasal congestion or stuffiness, runny nose (rhinorrhoea), cough, or sore throat OR Worsening of at least one of those symptoms, if symptoms are chronic OR Wheezing, sputum production, pleuritic chest pain, increased respiratory rate, signs on chest auscultation, hypoxia, increased supplemental oxygen requirement or new infiltrates on chest X-ray/CT - A positive RSV diagnostic test - Provided written informed consent Exclusion Criteria: - Is intubated and requires invasive ventilation - Has received any investigational RSV vaccine after HSCT, or has received any monoclonal anti-RSV antibodies within 4 months or 5 half-lives before participation - Treatment with intravenous ribavirin - Positive for test for influenza or parainfluenza - Significant untreated bacteraemia or fungaemia - Significant untreated bacterial, fungal, or viral pneumonia - Precluded from participating as a result of treatment with another investigational drug or participation in another clinical trial - Other disease or condition which would preclude the subject's participation in a clinical trial - Is receiving an antiretroviral protease inhibitor - Has chronic, active hepatitis infection - Known alcohol or drug abuse |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Birmingham Heartlands Hospital | Birmingham | |
United Kingdom | Bristol Haematology and Oncology Centre | Bristol | |
United Kingdom | Clatterbridge Cancer Centre NHS Foundation Trust | Liverpool | |
United Kingdom | St Georges University Hospital | London | |
United Kingdom | Manchester University NHS Foundation Trust | Manchester | |
United Kingdom | Nottingham University Hospital NHS Trust | Nottingham | |
United Kingdom | Sheffield Teaching Hospitals NHS Foundation Trust | Sheffield |
Lead Sponsor | Collaborator |
---|---|
Pulmocide Ltd |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | RSV viral load measured in nasal secretions by reverse transcription quantitative PCR (RT-qPCR) | Day 1 to Day 3 | ||
Primary | Proportion of participants reporting one or more treatment-emergent adverse event (TEAE) | Baseline to Day 28 | ||
Primary | Proportion of participants who discontinue due to an adverse event | Baseline to Day 28 | ||
Primary | Proportion of participants who meet the markedly abnormal criteria for 12-lead ECG assessment at lease once post dose | Baseline to Day 28 | ||
Primary | Proportion of participants who meet the markedly abnormal criteria for vital signs assessment at lease once post dose | Baseline to Day 28 | ||
Primary | Proportion of participants who meet the markedly abnormal criteria for safety laboratory assessment at lease once post dose | Day 1 to Day 28 | ||
Primary | Proportion of participants who meet the markedly abnormal criteria for peak expiratory flow assessment at lease once post dose | Day 1 to Day 28 | ||
Secondary | Average change in RSV load measured in nasal secretion | Day 1 to Day 7 | ||
Secondary | Change in RSV load in nasal secretion | Baseline to Day 3 | ||
Secondary | Change in RSV load in nasal secretion | Baseline to Day 7 | ||
Secondary | Duration in viral shedding measured in nasal secretion | Day 1 to Day 28 | ||
Secondary | Determination of nasal concentrations of PC786 | Days 1, 2, 3, 7, 14 and 28 | ||
Secondary | Maximum observed concentration (Cmax) of PC786 measured in plasma | Day 1, Pre-dose to 4 hours | ||
Secondary | Trough plasma concentration (Ctrough) of PC786 | Days 2 and 3, Pre-dose | ||
Secondary | Area under the concentration versus time curve from time zero to time at 4 hours (AUC0-4) of PC786 in plasma | Day 1, Pre-dose to 4 hours | ||
Secondary | Last quantifiable concentration (Ct last) of PC786 measured in plasma | Day 1, and multiple timepoints to Day 28 | ||
Secondary | Changes in RSV symptoms measured using a symptom diary card | Days 1, 2, 3, 4, 5, 6, 7, 14 and 28 | ||
Secondary | Proportion of participants developing lower respiratory tract infection (LRTI) or pneumonia | Day 1 to 28 | ||
Secondary | Proportion of participants progressing to invasive ventilation | Day 1 to 28 | ||
Secondary | Trends in oxygen saturation index | Day 1 to Day 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03698084 -
RESCEU: Defining the Burden of RSV Disease
|
||
Completed |
NCT04090658 -
A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults
|
Phase 1 | |
Completed |
NCT04231968 -
A Study of AK0529 in Chinese Infants Hospitalized With RSV
|
Phase 3 | |
Completed |
NCT03227029 -
Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
Completed |
NCT02873286 -
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
|
Phase 2 | |
Terminated |
NCT02948127 -
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
Withdrawn |
NCT02864628 -
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
|
Phase 1 | |
Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
Completed |
NCT02247726 -
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
|
Phase 2 | |
Completed |
NCT02237209 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
Completed |
NCT02040831 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
Completed |
NCT01915394 -
Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)
|
N/A | |
Completed |
NCT01355016 -
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00232635 -
A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT
|
Phase 2 | |
Completed |
NCT01155193 -
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
|
||
Not yet recruiting |
NCT06083623 -
A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants
|
Phase 2/Phase 3 | |
Terminated |
NCT02890381 -
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
Active, not recruiting |
NCT03422237 -
Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
Completed |
NCT03674177 -
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
|
Phase 1 | |
Completed |
NCT01968083 -
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 |